Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERVIT-MS: tolDC-VitD3 in Multiple Sclerosis
NCT02903537Phase 1Unknown
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Jul 2017
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides in multiple sclerosis (MS) (4 arms), sponsored by Germans Trias i Pujol Research Institute. Primary endpoints: Safety and Tolerability at 24 months, Neurologic changes at 24 months and 1 more. Status: unknown.
02
Drugs
Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02903537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903537.